A perillyl alcohol-3-bromopyruvate conjugate and methods of treating cancer
AssigneeNeOnc Technologies, Inc.
InventorThomas CHEN
Life of this patent
Estimating the term…
Abstract
NEO218 (3-bromo-2-oxo-propionic acid 4-isopropenyl-cyclohex-1-enylmethyl ester), (see formula 1), is a novel molecule that was generated by covalent fusion of two unrelated agents: 3-bromopyruvate (3-BF; an alkylating agent that Inhibits cancer cell metabolism) and perillyi alcohol (POH; a natural monoterpene with anticancer properties). Methods of synthesizing NBO218, pharmaceutical compositions comprising NBO218 and methods of treating cancer using NBO218 are also disclosed.
Claims10
A conjugate of perillyl alcohol and 3-bromopyruvate that is
- 3-bromo-2-oxo-propionic acid 4-isopropenyl-cyclohex-1-enylmethyl ester,
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising 3-bromo-2-oxo-propionic acid 4-isopropenyl-cyclohex-1-enylmethyl ester.
A method of treating a cancer in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of 3-bromo-2-oxo-propionic acid 4-isopropenyl-cyclohex-1-enylmethyl ester.
A process for synthesizing 3-bromo-2-oxo-propionic acid 4-isopropenyl-cyclohex-1-enylmethyl ester comprising:
- a) reacting 1,1-dichlorodimethyl ether with bromopyruvic acid to form 3-bromopyruvic chloride;
- and,
- b) reacting 3-bromopyruvic chloride with perillyl alcohol to form 3-bromo-2-oxo-propionic acid 4-isopropenyl-cyclohex-1-enylmethyl ester.
Dependencies are inferred from the claim text.